AbbVie/InterMune must show 'irreparable' harm from data disclosure, says top EU court
This article was originally published in SRA
Executive Summary
Efforts by AbbVie and InterMune to prevent the European Medicines Agency from disclosing clinical trial data on their products Humira and Esbriet have hit a hurdle after the EU's highest court set aside the interim measures granted to the companies by the General Court earlier this year1-3.